Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07726888) titled 'Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study' on July 21.

Study Type: Observational [Patient Registry]

Primary Sponsor: Second Affiliated Hospital of Wenzhou Medical University

Condition: Ulcerative Colitis (Disorder) Guselkumab

Intervention: Drug: Guselkumab

Recruitment Status: Not recruiting

Date of First Enrollment: August 1, 2026

Target Sample Size: 97

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07726888

Published by HT Digital Content Services with permission from Health Daily...